新辅助化疗对乳腺癌患者survivin、Ki-67、ER、C-erbB-2、p53和肿瘤组织学分级的影响及其疗效预测意义 |
| |
引用本文: | 林奇,陈慧玉,刘洋,唐强,金灌培.新辅助化疗对乳腺癌患者survivin、Ki-67、ER、C-erbB-2、p53和肿瘤组织学分级的影响及其疗效预测意义[J].实用肿瘤杂志,2010,25(4):400-404. |
| |
作者姓名: | 林奇 陈慧玉 刘洋 唐强 金灌培 |
| |
作者单位: | 连云港市第一人民医院普通外科,江苏,连云港,222002 |
| |
基金项目: | 江苏连云港市卫生局课题 |
| |
摘 要: | 目的探讨新辅助化疗对乳腺癌survivin、Ki-67、ER、C-erbB-2、p53和肿瘤组织学分级的影响,同时研究这些指标对新辅助化疗的疗效预测作用。方法通过免疫组织化学S-P法检测和HE染色对化疗前空芯针穿刺标本和化疗后手术切除的30例乳腺癌组织的survivin、Ki-67、ER、C-erbB-2、p53和肿瘤组织学分级的表达情况。化疗方案为CAF(CTX 600 mg/m^2,THP 50 mg/m2,5-FU500 mg/m^2)和TA(艾素75 mg/m^2,THP 30 mg/m^2),每3周1疗程,用药2~3个疗程。化疗疗效通过采用临床体检、乳腺彩超检测及术后病理分析综合判断。结果 30例患者中70.0%(21/30)获PR,SD为30.0%(9/30),全组无恶化病例,总有效率为70.0%(21/30)。通过对化疗前后的指标比较发现:新辅助化疗能降低Ki-67的表达(P〈0.01)和肿瘤分级(P〈0.05)。化疗前后survivin、ER、C-erbB-2和p53表达无明显变化(P〉0.05)。Ki-67高表达(≥20%)、肿瘤分级高的患者和Ki-67低表达(〈20%)、肿瘤分级较低的患者相比,化疗疗效更明显(P〈0.05)。结论新辅助化疗能显著降低乳腺癌组织Ki-67的表达和肿瘤分级,而对survivin、ER、C-erbB-2和p53表达均无显著影响,Ki-67高表达(≥20%)、肿瘤分级高的患者对化疗更敏感、短期疗效更显著。
|
关 键 词: | 乳腺肿瘤/药物疗法 乳腺肿瘤/病理学 化学疗法 辅助 肿瘤分期 基因 p53 Ki-67抗原 基因 Bcl-2 |
Expression of survivin,Ki-67,ER,C-erbB-2 and p53 in neoadjuvant chemotherapy and its predictive value for therapeutical response of breast cancer |
| |
Institution: | LIN Qi,CHEN Hui-yu,LIU Yang,et al(Department of General Surgery,The First Hospital of Lianyungang City,Lianyungang,222000,China) |
| |
Abstract: | Objective To investigate the expression of survivin,Ki-67,estrogen receptor,C-erbB-2 and p53 in neoadjuvant chemotherapy and its predictive value for therapeutic response of breast cancer.Methods Thirty patients with breast cancer were treated with three cycles of CAF(CTX 600 mg/m2,ADM 50 mg/m2,5-FU 500 mg/m2) and TA(docetaxel 75 mg/m2,THP 30 mg/m2).Tumor response was assessed by clinical examination,B ultrasonography and pathological assessment;tumor grade was scored according to the Elston-Ellis classification.The immunohistochemical staining S-P method was used to examine the expression of survivin,Ki-67,estrogen receptor,C-erbB-2 and p53.Results The overall response rate was 70.0%(21/30),stable disease was 30.0%(9/30),and no progressive disease.Tumor grade(P〈0.05)and the expression of Ki-67(P〈0.01)were high before treatment,and were lower after chemotherapy,but the expression of estrogen receptor,C-erbB-2,p53 was not changed(P〉0.05).Compared to the lower tumor grade and lower Ki-67 count,the higher tumor grade and higher Ki-67 were related to better response(P〈0.05).Conclusions The expression of Ki-67 and tumor grade may decrease in neoadjuvant chemotherapy for breast cancer,but the expression of estrogen receptor,C-erbB-2 and p53 is not changed.The high tumor grade,high Ki-67 might be associated with better response. |
| |
Keywords: | breast neoplasms/drug therapy breast neoplasms/pathology chemotherapy adjuvant neoplasm staging genes p53 Ki-67 antigen |
本文献已被 维普 万方数据 等数据库收录! |
|